DrugPatentWatch Database Preview
Drugs in Development Information for TAK-438
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for TAK-438?
TAK-438 is an investigational drug.
There have been 330 clinical trials for TAK-438.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are sixteen US patents protecting this investigational drug and one hundred and thirty-four international patents.
Summary for TAK-438
| US Patents | 16 |
| International Patents | 134 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2016-06-01) |
| Vendors | 45 |
Recent Clinical Trials for TAK-438
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants | Millennium Pharmaceuticals, Inc. | Phase 1 |
| A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants | Takeda | Phase 1 |
| Effect of TAK-071 on Falls in Patients With Parkinson Disease | Takeda | Phase 2 |
Clinical Trial Summary for TAK-438
Top disease conditions for TAK-438
Top clinical trial sponsors for TAK-438
US Patents for TAK-438
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-438 | Start Trial | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | Takeda Pharmaceutical Company Limited (Osaka-Shi, JP) | Start Trial |
| TAK-438 | Start Trial | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-438 | Start Trial | Method for producing sulfonyl chloride compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP) | Start Trial |
| TAK-438 | Start Trial | Acid secretion inhibitor | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| TAK-438 | Start Trial | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-438
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-438 | China | 102421753 | 2029-02-25 | Start Trial |
| TAK-438 | China | 104211618 | 2029-02-25 | Start Trial |
| TAK-438 | China | 105524046 | 2029-02-25 | Start Trial |
| TAK-438 | China | 108129374 | 2029-02-25 | Start Trial |
| TAK-438 | European Patent Office | 2402313 | 2029-02-25 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
